Skip to content
Calculator

TB-500, BPC-157 and KPV blend (45 mg)

This three-peptide vial swaps the GHK-Cu of the better-known repair blends for KPV and puts TB-500 in charge: 25 mg of TB-500 with 10 mg each of BPC-157 and KPV. Its three ingredients are the three repair peptides FDA's advisory committee voted on in July 2026, which makes it a useful case study in what that vote did and did not change. Sellers often call it 'Tri-Heal'; the name is a market nickname, not an ingredient list, and the same name can mean different contents.

As sold, one vial: TB-500 25 mg, BPC-157 10 mg, KPV 10 mg. Statuses as of October 3, 2026. Reviewed by the Grey Peptides Editorial Board. Nothing here is a recommendation or a dose, and no seller is named or linked.

Each component at a glance

From our encyclopedia and FDA's July 2026 Pharmacy Compounding Advisory Committee record. Evidence grades follow the rubric on our methodology page.

ComponentEvidenceFDA statusPCAC, July 2026WADA 2026WADA 2027Interactions
TB-500LowResearch ChemicalRecommended (8-6, July 23, 2026); FDA has not actedProhibited (S2.3)Prohibited (S2.3)Partly reviewed
BPC-157LowResearch ChemicalRecommended (8-6, July 23, 2026); FDA has not actedProhibited (S0)Prohibited (S0)Partly reviewed
KPVLowResearch ChemicalRecommended (8-6, July 23, 2026); FDA has not actedProhibited under S0 (not named)Prohibited under S0 (not named)Not yet reviewed

What one vial contains: the ratio arithmetic

The vial holds 45 mg in total. Whatever volume of water is added and however much is drawn, every draw carries the components in the same proportions. The table expresses each as a share of the vial, as a multiple of the smallest component (BPC-157), and as a concentration if the whole vial were dissolved in 2 mL or 3 mL of water. These are arithmetic illustrations of what is in the vial, not suggested volumes or doses.

ComponentIn the vialShare× BPC-157In 2 mLIn 3 mL
TB-50025 mg55.6%2.512.5 mg/mL8.33 mg/mL
BPC-15710 mg22.2%15 mg/mL3.33 mg/mL
KPV10 mg22.2%15 mg/mL3.33 mg/mL

The Blend & Stack Calculator runs the same arithmetic for any volume and draw, with this composition as a preset (TB-500, BPC-157 and KPV, 45 mg (25/10/10)).

What is in the vial, as sold

Our Name Decoder found two listings for this composition, both stating TB-500 25 mg, BPC-157 10 mg and KPV 10 mg in a 45 mg vial. That is a small sample, and other vials sold under similar names may differ. TB-500 makes up 55.6% of the vial by weight, two and a half times each of the other two, so the arithmetic table above is dominated by it in the same way GHK-Cu dominates the 70 mg and 80 mg blends.

TB-500: the largest share, the parent's evidence

TB-500 is a seven-amino-acid fragment of thymosin beta-4, and the human research is on that 43-residue parent protein, not on the fragment. Thymosin beta-4 has been given intravenously to healthy volunteers in a randomised safety study1, applied to venous leg ulcers in a multicentre trial2, and taken to phase 3 as eye drops for corneal disease3. Injected TB-500 as sold has no human trial. Reviews of thymosin beta-4 note its role in tumour biology as well as repair4, which matters more in a vial where it is the largest ingredient.

BPC-157

BPC-157's support comes from rodent healing studies, many from one group5. Its human record is a two-person intravenous safety pilot with no control group6 and a single-clinic knee chart review of 16 patients reached by phone7. A 2025 systematic review found preclinical support for musculoskeletal healing and noted that clinical use has outpaced the evidence8.

KPV: never tested in people

KPV is lysine-proline-valine, the last three amino acids of alpha-MSH. In mice it reduced the severity of chemically induced colitis when given in drinking water, and in human gut cells nanomolar amounts blocked NF-kappaB and MAP kinase signalling, entering the cells through a transporter called PepT19. Further mouse studies found faster recovery in two colitis models10. No published study has tested KPV in people, by any route, for anything.

KPV also raises a practical question for any blend. A laboratory stability study found that under acid, alkali and oxidising stress KPV breaks down mainly into a cyclic dipeptide, a diketopiperazine11. That study did not test KPV mixed with other peptides, but it is a reminder that what is in a reconstituted vial after days in a refrigerator is not necessarily what was on the label, and nobody has published stability data for these three peptides stored together.

Has the mix been studied?

No. KPV has not been combined with either of the others in any published study. The only combination data for the other two are a 2026 rat Achilles tendon study, in which TB-500 alone improved tendon strength while BPC-157 alone did not reach significance12, and four patients in the 2021 knee chart review who received BPC-157 with thymosin beta-47. A 25 to 10 to 10 ratio of these three peptides has never been tested in any species.

What the July 2026 vote changed, and what it did not

All three ingredients came before FDA's Pharmacy Compounding Advisory Committee on July 23, 2026, and each was recommended for the compounding list by 8 votes to 6 with one abstention, against the advice of FDA's reviewers13. It is tempting to read that as approval. It is not. A recommendation is advice to FDA; as of October 3, 2026, FDA had not acted on it, so none of the three can yet be lawfully compounded. Even if FDA adopts every vote, the compounding list allows a pharmacy to prepare a listed substance for an individual patient's prescription. It does not approve the substance as safe or effective, and it does not cover a pre-mixed vial sold online. FDA continues to send warning letters to sellers of peptides labelled for research use only14.

Living with a 2.5-to-1 ratio

In this vial, any draw chosen for an amount of BPC-157 or KPV carries two and a half times as much TB-500. Raising one raises all three; stopping one stops all three. If something goes wrong, there is no way to know which of the three caused it. The Blend & Stack Calculator makes the arithmetic visible for any volume. The arithmetic says what is in a draw; it says nothing about whether any amount is safe or useful, which for these three has not been established in people.

For tested athletes

All three are prohibited at all times. BPC-157 is named under S0, non-approved substances, and TB-500 under S215. KPV is not named, but as a substance with no current approval for human use it falls under the S0 catch-all15. Strict liability applies whatever the label said.

What to check

Ask for the milligrams of each peptide and a certificate of analysis that quantifies all three by name, from an identified laboratory, for the batch in hand; a report that covers only TB-500 says nothing about the KPV or BPC-157. Our COA Decoder explains what a genuine report contains. For the better-known repair mixes, see the BPC-157 and TB-500 blend and the four-peptide blend.

Sources

  1. Ruff, D., et al. (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci, 1194. PubMed 20536472 ↗
  2. Guarnera, G., et al. (2007). Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci, 1112. PubMed 17495250 ↗
  3. Sosne, G. (2018). Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther, 18. PubMed 30063853 ↗
  4. Bjørklund, G., et al. (2020). Thymosin β4: A Multi-Faceted Tissue Repair Stimulating Protein in Heart Injury. Curr Med Chem, 27. PubMed 31333080 ↗
  5. Seiwerth, S., et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des, 24. PubMed 29998800 ↗
  6. Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31. PubMed 40131143 ↗
  7. Lee, E., et al. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 27. PubMed 34324435 ↗
  8. Vasireddi, N., et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 21. PubMed 40756949 ↗
  9. Dalmasso, G., et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134. PubMed 18061177 ↗
  10. Kannengiesser, K., et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis, 14. PubMed 18092346 ↗
  11. Pawar, K. R., et al. (2015). Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates. Biomed Chromatogr, 29. PubMed 25298219 ↗
  12. Biçer, O., et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 37. PubMed 42542926 ↗
  13. U.S. Food and Drug Administration. July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee: votes on BPC-157, KPV and TB-500 (8 yes, 6 no, 1 abstain each). Page current as of August 6, 2026; re-read October 3, 2026. Source ↗
  14. U.S. Food and Drug Administration. Warning letter 694608 to an online seller of peptides labelled for research use only, December 10, 2024. Source ↗
  15. World Anti-Doping Agency. The 2026 Prohibited List (S0; S2), in force January 1 to December 31, 2026; the 2027 List keeps the same statuses. Read in full July 16, 2026. Source ↗

Related: the blends and stacks hub, the Name Decoder, the COA Decoder and the Interaction Matrix. Last updated October 3, 2026.